Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erba expands into US with $6.5m Escalon Dx acquisition

This article was originally published in Clinica

Executive Summary

German in vitro test kit manufacturer Erba Diagnostics has bought Escalon Medical's clinical diagnostics business for $6.5 million in cash, giving it a footprint in the US. The deal also provides Erba with new testing capabilities, as well as a business that brought in $13 million in the 12 months ending 30 June. Mannheim-based Erba currently specialises in OEM products including clinical, haematology, urine and electrolyte analysers; and ELISA devices, and reagents and accessories. It has a presence in Latin America, Europe, Africa, Russia, the Middle East and Asia. Escalon's diagnostic business comprises Drew Scientific (Dallas, Texas), which produces glycated haemoglobin (HbA1c) analysers for diabetes monitoring and haematology instruments; and JAS Diagnostics (Miami Lakes, Florida), which specialises in a range of liquid stable diagnostic chemistry reagents for OEM use.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT099475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel